Published Date: 24-Jun-2021
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report Global Erythropoietin Drugs Market, published by KBV research, The Global Erythropoietin Drugs Market size is expected to reach $20.2 billion by 2027, rising at a market growth of 11.8% CAGR during the forecast period.
Renal diseases acquired the highest revenue share of the global market of erythropoietin drugs in 2020. It is due to the increasing occurrences of anaemia at a constant rate. The first erythropoietin drug was Epogen. This drug got approval by the U.S. FDA for the treatment of anaemia caused by CKD because of the early introduction of this drug CKD treatment and increasing incidence of the same. This segment is expected to grow at a significant rate.
In the product segment, Epoetin-alfa procured the highest revenue share in the market in 2020. It is due to its increasing adoption by healthcare experts. It is restricted the production of any other recombinant human erythropoietin drug. Other medications like epoetin-zeta and epoetin-omega are anticipated to witness a promising growth rate during the forecast period. The biosimilar formulations of epoetin-alfa are more effective in treating anemic conditions. Mircera by F. Hoffmann-La Roche Ltd. and EporatiobyTeva Pharmaceutical Industries, Ltd. are major products in this segment.
The North America market dominated the Global Erythropoietin Drugs Market by Region in 2020. Asia-pacific showcase the highest growth rate during the forecast period. The growth of the erythropoietin drug market in this region is due to the presence of several companies for erythropoietin drugs. The region is among the top regions in the biosimilar industry. It is owing to the presence of major manufacturers of biosimilars in these regions. India and China are among the major erythropoietin biosimilar markets. The development cost of biosimilars in India ranges from $10 and $20 million due to a favorable industrial environment and supportive government legislation.
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Johnson and Johnson, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., F. Hoffmann-La Roche Ltd., Biocon Limited, Intas Pharmaceutical Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., LG Corporation (LG Life Sciences Ltd.), and Celltrion, Inc.
By Drug Class
Unique Offerings from KBV Research